ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO668

Safety of Liraglutide versus Placebo in Patients with T2D and CKD in the LEADER Trial

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical

Authors

  • Mann, Johannes F., KfH Kidney Center, Munich, Germany
  • Fonseca, Vivian A., Tulane University Medical Center, New Orleans, Louisiana, United States
  • Mosenzon, Ofri, Hadassah Hebrew University Hospital, Jerusalem, Israel
  • Raz, Itamar, Hadassah Hebrew University Hospital, Jerusalem, Israel
  • Frimer-Larsen, Helle, Novo Nordisk A/S, Soborg, Denmark
  • Von Scholten, Bernt Johan, Novo Nordisk A/S, Soborg, Denmark
  • Idorn, Thomas, Novo Nordisk A/S, Soborg, Denmark
  • Poulter, Neil, Imperial College, London, United Kingdom

Group or Team Name

  • On behalf of LEADER Trial Steering Committee and Investigators
Background

We assessed the safety of liraglutide vs placebo (PBO) in patients with chronic kidney disease (CKD) in the LEADER trial.

Methods

LEADER was a randomized, double-blind, multicenter, placebo-controlled cardiovascular (CV) outcome trial assessing CV and long-term safety of liraglutide up to 1.8mg/day vs PBO plus standard of care for 3.5-5 years in 9340 type 2 diabetes (T2D) patients at high risk for CV disease. We stratified participants according to baseline estimated glomerular filtration rate (eGFR) <60 (with CKD) or ≥60ml/min/1.73m2 (without CKD) and analyzed: serious adverse events (SAEs), SAEs leading to discontinuation, acute renal failure, nausea leading to discontinuation, acute gallstone disease, severe hypoglycemia and foot ulcers.

Results

Mean eGFR in patients with (n=2158) or without CKD (n=7158) was 45.7±10.9 and 90.8±21.6mL/min/1.73m2, respectively. There was no increased risk of SAEs or SAEs leading to discontinuation with liraglutide vs PBO in those with and without CKD (Fig); and no conclusive risk of acute renal failure in those with CKD (hazard ratio [HR] 0.82, confidence interval [CI] 0.61;1.10) or without CKD (HR 1.26, CI 0.88;1.79) with liraglutide vs PBO. There was no difference in the risk of nausea leading to discontinuation or acute gallstone disease in patients with and without CKD. Severe hypoglycemia risk was significantly reduced with liraglutide by 37% (with CKD, HR 0.63, CI 0.43;0.91) and non-significantly reduced by 19% (without CKD, HR 0.81, CI 0.59;1.12). Diabetic foot ulcer risk was not increased with liraglutide in those with and without CKD (Fig).

Conclusion

In LEADER, liraglutide was as well tolerated in patients with CKD as in those without CKD.

Funding

  • Commercial Support